From Research at med.fsu.edu Fri Oct 15 07:45:30 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 15 Oct 2021 11:45:30 +0000 Subject: Weekly funding opportunities In-Reply-To: <41BE50F4-38EF-426E-9038-3AE77A7406A3@fsu.edu> References: <41BE50F4-38EF-426E-9038-3AE77A7406A3@fsu.edu> Message-ID: Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Optional The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance COVID-19 health equity research. The following studies are encouraged under this FOA. * Proposals that advance diversity in COVID-19/COVID-19 variant clinical trials including efforts that (a) identify barriers to enrollment for underrepresented populations (e.g. racial, ethnic minorities), (b) advance evidence for racial and ethnic clinical trial data, (c) employ innovative strategies/trainings/education methods to increase enrollment for underrepresented populations in clinical trials (e.g. racial, ethnic minorities), and/or (d) improve communication strategies and informed messages for underrepresented populations (e.g. racial, ethnic minorities). * Proposals that advance equity in COVID-19 data including efforts that (a) increase evidence to support evaluation of outcomes of FDA-regulated products by demographic data including, but not limited to, ethnicity, race, age, and geography, and/or (b) leverage big data, novel data sources and artificial intelligence/machine learning options to contribute to informing the continued evaluation of the safety and efficacy of FDA-approved products (therapeutics, diagnostics, and vaccines) or products subject to EUAs/EUA expansion. * Proposals that increase understanding of diverse voices affected by COVID-19, including efforts that (a) support research to leverage novel data sources to understand diverse patient preferences and unmet needs, and/or (b) support expansion of culturally and linguistically tailored education (e.g., patient, healthcare providers). Due November 29, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday). Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24 Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) invites qualified academic or research institutions to apply for support to purchase and install advanced equipment to enhance and modernize research-supporting operations of biomedical research facilities. Targeted are core facilities, animal research facilities, and other research spaces that are used on a shared basis. The goal of this FOA is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficacy of their operation. To ensure proper installation and functioning of the equipment, minor alteration and renovation (A&R) efforts can be included as a small component of the budget. Due December 1, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday). HEAL Initiative: Advancing Health Equity in Pain Management (R61 / R33 Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventions?that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities (HDPs) in the United States?to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Expected outcomes of this initiative include evidence-based interventions that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and/or 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management. Studies that address multiple socioecological domains and levels of influence (e.g. organizational/institutional, community/neighborhood, societal) to advance health equity and mitigate health disparities in pain management are of higher priority. Studies must address research topics within the mission and research interests of participating NIH Institutes and Centers. Due December 9, 2021. Med-RA deadline to receive draft documents: November 29. Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 ? Clinical Trial Optional) The purpose of this FOA is to solicit Research Project Grant (R01) applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of the stigmas at individual levels. Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or care givers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs). Due December 20, 2021 and December 20, 2022. Med-RA deadline to receive draft documents for December 2021 due date: December 7. Systems Biology for Infectious Diseases (U19 Clinical Trial Not Allowed) The purpose of the Funding Opportunity Announcement (FOA) is to support research that employs systems biology approaches to human pathogens. The approach will generate and integrate large datasets into models that guide in vitro, in vivo and clinical studies, with the goals of predicting disease severity, predicting responses to vaccines and therapeutics, and identifying candidate targets for interventions. Due January 14, 2022. Med-RA deadline to receive draft documents: January 3. Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional) The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement is encouraged. Due February 1, 2022; February 1, 2023; and February 1, 2024. Med-RA deadline to receive draft documents for February 2022 due date: January 19. Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs. Due February 4, 2022. Med-RA deadline to receive draft documents: January 24. Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 / R01) Clinical Trial Not Allowed) R21 R01 The purpose of these funding opportunity announcements (FOAs) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to these FOAs should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to these FOAs are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. Standard dates apply. Expires January 8, 2025. Med-RA deadline to receive draft documents for February 5, 2022 (R01) standard date: January 25; for February 16, 2022 (R21) standard date: February 3. Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative, discovery research studies to better characterize early-life risk factors and elucidate underlying causal mechanisms through which these risk factors contribute to the development of obesity during infancy and early childhood. Studies should aim to understand biological mechanisms that mediate behavioral and/or metabolic risk for obesity development in young children and how risk may be modified by other contributors such as psychosocial, contextual, and/or environmental factors. This FOA encourages multidisciplinary teams of scientists including, but not limited to those with expertise in basic, translational, clinical, and behavioral research. Due March 8, 2022. Med-RA deadline to receive draft documents: February 23. Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer?s Disease and Related Dementias (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) supports mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer?s Disease and Alzheimer?s Disease Related Dementias (AD/ADRD). It is expected that these studies will address the clinical relevance of these exposures on disease initiation, progression, or modification. Anticipated outcomes include an improved understanding of neurological mechanisms of chemical toxicities related to AD/ADRD, more evidence-based potential biomarkers of exposure and toxicity for those most at risk, as well as more data to support causality and potential approaches for mitigation. The scope of research includes mechanistic studies on the modification of known AD/ADRD targets by neurotoxins of concern, and conversely, whether known targets for these neurotoxins play a role in etiologies of AD/ADRD. The development and validation of neuropathological, neurophysiological and neurobehavioral animal models that simulate potential toxin exposures in humans is another example of supported studies. Preclinical studies of interactions of environmental toxicant with AD/ADRD in pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA. Interdisciplinary collaboration is required to address the various fields of study related to this research, e.g., neuroscience, aging, and environmental health sciences. Due March 11, 2022. Med-RA deadline to receive draft documents: February 28. Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) Through this funding opportunity announcement, the National Cancer Institute encourages the submission of exploratory/developmental research grant applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical). Due June 7, 2022; October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; and October 8, 2024. Med-RA deadline to receive draft documents for June 2022 due date: May 24 (due to Memorial Day holiday). Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery R01 Clinical Trial Required This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. R01 Basic Experimental Studies with Humans Required This funding opportunity announcement invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. NIH considers such studies as Basic Experimental Studies with Humans that are prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials. Applications should not propose a goal of clinical outcomes or products. R01 Clinical Trials Not Allowed This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. Due June 21, 2022; June 21, 2023; and June 21, 2024. Med-RA deadline to receive draft documents for June 2022 due date: June 8. Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages primary care practice-based research focused on rigorous evaluations of factors that impact or account for the effectiveness of existing suicide prevention practices and/or pilot clinical trials aimed at optimizing and pilot testing patient-, provider-, or systems-level suicide prevention strategies. Applications of interest include those that refine and test scalable strategies for use in primary care across different intercepts in the chain-of-care, including strategies for identifying individuals at risk, assessing and stratifying risk, providing brief interventions, promoting initial and ongoing engagement in indicated services, continued outcome monitoring and follow-up, and tracking patient outcomes. For purposes of this FOA, primary care is defined as pediatric practice, family practice, obstetrics/gynecology, internal medicine, and geriatric practice. Primary care practices range in size, resources and patient health needs; proposed strategies should meet the practice needs to be feasible, scalable, sustainable, and practice-ready. NIMH encourages prevention approaches that incorporate the use of mHealth (the use of mobile and wireless devices [cell phones, tablets, etc.]) and other design features that can facilitate scalability and sustainability, and deployment-focused research approaches that take into account the perspectives of key stakeholders (e.g., patients, providers, administrators) and system-level factors such as setting resources, workforce capacity, and training needs. This FOA also encourages studies that examine suicide prevention strategies that have broad reach, including potential for addressing risk among individuals who experience mental health service disparities (e.g., racial/ethnic minority groups; sexual and gender minorities, individuals living in rural areas, socioeconomically disadvantaged persons), and studies that explore how the proposed strategies can reduce health disparities and promote health equity. Due June 21, 2022. Med-RA deadline to receive draft documents for June 2022 due date: June 8. Sanofi US Educational Grants Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes. Sanofi US is currently accepting educational grant applications in the following therapeutic area(s): * US Cardiovascular, specific to the Area of Interest: * The role of AADs in Early Rhythm Control and the Management of Atrial Fibrillation * US Multiple Sclerosis * US and Global Oncology, specific to the Area of Interest: * Breast Cancer * US Oncology, specific to the following Areas of Interest: * Prostate Cancer * Tumor Lysis * HSCT: stem cell mobilization and collection during autologous HSCT * US and Global Rare Blood Disorder, specific to the Areas of Interest: * Hemophilia * Cold Agglutinin Disease (CAD) * Acquired Thrombotic Thrombocytopenic Purpura (aTTP) * Immune Thrombocytopenia (ITP) * US and Global Rare Genetic Diseases, specific to the Areas of Interest: * Acid sphingomyelinase deficiency (ASMD) * Fabry Disease * Gaucher Disease * Pompe Disease * MPS1 * Lysosomal Storage Disorders * Other Genetic Disorders * US Transplantation, specific to the Area of Interest: * Immunosuppressive Strategies to Reduce Transplant Rejection The Sanofi-Regeneron Alliance is currently accepting educational grant submissions in the following therapeutic area(s): * US and Global Immunology, specific to the following Area(s) of Interest: * Atopic Dermatitis * Chronic Spontaneous Urticaria (CSU) * Prurigo Nodularis (PN) * US and Global Immunology/Respiratory, specific to the following Area of Interests, will be managed by Regeneron * Asthma * Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) * Eosinophilic Esophagitis (EoE) Due at least 12-16 weeks in advance of request for notification date. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Oct 20 15:38:43 2021 From: Research at med.fsu.edu (med-Research) Date: Wed, 20 Oct 2021 19:38:43 +0000 Subject: Toffler Scholar Program Funding Opportunity Message-ID: The College of Medicine is excited to announce a new funding cycle for the Toffler Scholar Program for FSU health science researchers! The Toffler Scholar Program was created by the Trustees of the Karen Toffler Charitable Trust, a 501 C3 nonprofit foundation focused on early-stage research that advances the medical field in profound, high-impact ways. Tapping into the deep legacy of their founders, best-selling authors and futurists, Alvin and Heidi Toffler, the trust exists to be a catalyst for future-focused breakthroughs. The Toffler Scholar Program focuses on helping university health science (basic to translational) researchers gain access to support and a network for often underfunded innovations. It is a nimble source of financial support for FSU medical researchers working on early-stage, future-focused brain science. Together with the Florida State University College of Medicine, the program helps foster new ways of thinking and problem solving to find solutions to humanity's most difficult problems. Toffler Scholar grants are one-year grants of $60,000. Please see this link for eligibility and application details: https://med.fsu.edu/researchdivision/toffler-scholar-program Jeffrey N. Joyce, Ph.D. Senior Associate Dean for Research and Graduate Programs Professor of Biomedical Sciences FSU CTSA PI, "Together: Transforming and Translating Discovery to improve Health" https://ctsa.research.fsu.edu/ Florida State University College of Medicine Suite 1110-J 1115 West Call Street Tallahassee, FL 32306-4300 850-644-2190 Email Jeffrey.Joyce at med.fsu.edu ORCID iD https://orcid.org/0000-0002-0131-0946 -------------------------------------------------------------------------------- Selene Borras Senior Administrative Specialist for the Division of Research and Graduate Programs Email: selene.borras at med.fsu.edu Office: 850-644-2237 Fax (850) 645-1420 1115 West Call Street Room 1110-H Tallahassee, Florida 32306-4300 [cid:image001.jpg at 01D7C5C6.56A7C130] -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.jpg Type: image/jpeg Size: 12774 bytes Desc: image001.jpg URL: From Research at med.fsu.edu Fri Oct 29 13:37:14 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 29 Oct 2021 17:37:14 +0000 Subject: Weekly funding opportunities In-Reply-To: <2F47BD77-BA41-456D-A563-E893A7EF9EDA@fsu.edu> References: <2F47BD77-BA41-456D-A563-E893A7EF9EDA@fsu.edu> Message-ID: American Diabetes Association: Leveraging Nutrition and Lifestyle for Diabetes Prevention Across the Life Span The American Diabetes Foundation is soliciting research to improve the adoption of lifestyle modifications at the individual and community level with interventions tailored to different racial and socioeconomic groups across the life span. Applicants should indicate how the proposed research will have a significant impact (?move the needle?) on outcomes in those individuals at risk of, or living with, diabetes. This RFA prioritizes nutritional and/or physical activity interventions that more effectively incorporate cultural or personal preferences, psychological supports, comorbid conditions, socioeconomic status, food insecurity, and other factors that may impact consistency with an eating and/or exercise plan and its effectiveness; approaches that better tailor medical nutrition therapy and diabetes self-management education and support to different racial and socioeconomic groups in sustainable real-world settings; behavioral interventions that help encourage and sustain health diet and increased physical activity; comparison and/or utilization of different delivery methods aided by wearable technology (e.g. accelerometers, continuous glucose monitors, etc.); and cost-effectiveness studies in support of third-party coverage and policy change. Letter of Intent due November 22, 2021. Med-RA deadline to receive draft documents: November 8 (due to Veterans Day holiday). Marsha Rivkin Center for Ovarian Cancer: Research Grants Pilot Study Program Two-year awards of total $75,000. Pilot Study Program awards will support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. Funds are for direct costs only. Due December 1, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday). Scientific Scholar Award Two-year grants at $120,000 each, Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only. Due December 1, 2021. Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday). McKnight Foundation: Technological Innovations in Neuroscience Awards The program seeks to advance and enlarge the range of technologies available to the neurosciences. It does not support research based primarily on existing techniques. The Endowment Fund is especially interested in how technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited. Up to $100,000 per year for two years. Funds may be used toward a variety of research activities but not the recipient?s salary. Letter of Intent due December 6, 20121. Med-RA deadline to receive draft documents: November 18 (due to Thanksgiving holiday). Chan Zuckerberg Initiative: Data Insights from Existing Single-Cell Datasets The Chan Zuckerberg Initiative (CZI) seeks applications for projects that aim to use and gain insights into health and disease from existing single-cell datasets to help accelerate progress toward challenges associated with the compilation and exploration of large atlas-scale data. Given the growth of single-cell biology and the rapid increase in available data, CZI is looking to support projects that will advance the fields of single-cell biology and data science. Grantees will be expected to interact with a network among participating groups that builds community and accelerates progress. Applications are encouraged from computational experts outside the field of single-cell biology but with expertise relevant to overcoming current bottlenecks. Projects may include dedicated efforts to refine existing computational tools, benchmark classes of tools, improve standards, integrate available data that enables greater biological insight, develop new features that support interoperability of data or tools, and other major challenges brought forward. 18-month projects; focused projects: $200,000; expanded projects: $400,000. Due December 14, 2021. Med-RA deadline to receive draft documents: December 1. NIH Health Care Systems Research Collaboratory ? Pragmatic and Implementation Trials of Embedded Interventions (UG3 / UH3, Clinical Trials Optional) This Funding Opportunity Announcement (FOA) encourages UG3 / UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve health and care delivery, with a particular focus on health care systems (HCS) with less historical involvement in research studies focused on improving health outcomes for US patient populations. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a trial conduct phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The overall goal of this initiative is to support the ?real world? assessment of health care strategies and clinical practices and procedures in HCS that lead to improved care for populations in a variety of healthcare contexts, with a strong focus on populations with health disparities. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA requires that the intervention under study be embedded into health care delivery system, ?real world? settings. Studies can propose to integrate multimodal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve adherence to evidence-based guidelines. Trials should be conducted across three or more health care systems (HCS) that provide care to patient populations and will become part of and work with the NIH HCS Research Collaboratory. Due December 15, 2021 and June 2, 2022. Med-RA deadline to receive draft documents for December 2021 due date: December 2. Expanding Differentiated Care Approaches for Adolescents Living with HIV (R34 / R01 Clinical Trial Optional) R34 This Funding Opportunity Announcement invites applications for Planning Grants (R34) that will develop and pilot test differentiated models of care for adolescents and young adults (referred to in this FOA as youth) who are living with HIV around the world. Differentiated care models can be designed to maintain or improve health outcomes along the HIV care continuum for youth who are living with HIV. R01 This Funding Opportunity Announcement invites applications for Research Project Grants (R01) that will evaluate differentiated models of care for adolescents and young adults (referred to in this FOA as youth) who are living with HIV around the world. Differentiated care models can be designed to maintain or improve health outcomes along the HIV care continuum for youth living with HIV. Due January 6, 2022. Med-RA deadline to receive draft documents: December 13 (due to Winter break). Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as ?liquid biopsies?, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for ?liquid biopsies?, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices. Due January 11, 2022; June 7, 2022; September 13, 2022; January 11, 2023; June 7, 2023; September 13, 2023; January 11, 2024; June 7, 2024; and September 13, 2024. Med-RA deadline to receive draft documents for January 2022 due date: December 13 (due to Winter break). Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human The purpose of this FOA is to solicit applications for the development of novel, untested analytics and technologies to identify and map senescent cells in human tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds. Due January 18, 2022. Med-RA deadline to receive draft documents: January 4 (due to MLK holiday). Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed) The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple murine and/or human tissues, optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Due January 19, 2022. Med-RA deadline to receive draft documents: January 5 (due to MLK holiday). Maternal and Child Health Secondary Data Analysis Research (MCH SDAR) The purpose of the Maternal and Child Health Secondary Data Analysis Research (MCH SDAR) Program is to support applied MCH research that utilizes the secondary analysis of existing national data sets and/or administrative records to improve the health and well-being of MCH populations. The MCH SDAR program provides the opportunity for researchers across the nation to build the MCH evidence base by using existing data sets, such as national data sets and/or administrative records, to identify emerging issues, study new research questions, test hypotheses, and determine pathways for intervention. Existing and emerging public health challenges affecting MCH populations including children with special health care needs require timely, evidence-based responses from MCH programs, policy, and practice. Without sufficient evidence or data, it is challenging to develop interventions addressing both existing and emerging MCH issues. This program will allow us to achieve timely, evidence-based responses to these challenges. HRSA will fund approximately six 1-year projects at $100,000 per project. Due January 26, 2022. Med-RA deadline to receive draft documents: January 12 (due to MLK holiday). NSF Ideas Lab: Dark Dimensions of the RNA Regulome This solicitation invites participation in an Ideas Lab whose focus will be the exploration of novel approaches to elucidate the evolutionary and functional significance of RNA transcripts that do not encode proteins as well as the technological innovations that may arise from the ability to harness the power of non-coding RNA to solve pressing societal problems. Ideas Labs are intensive, facilitated workshops to find innovative solutions to grand challenge problems. The overarching aim of this Ideas Lab is to bring together a diverse set of researchers from multiple disciplines spanning biology, chemistry, physics, mathematics, computer and information sciences, and engineering, to stimulate generation and execution of innovative research that advances our understanding of the origin, diversity, and functions of non-coding RNAs. Outcomes from this Ideas lab should lead to new theories and models for understanding non-coding RNAs, new approaches to manipulate and control non-coding RNA activity, and biotechnological innovations based on the expected research results that spur the bioeconomy and enhance our ability to predict and mitigate the effects of changing environments on organisms and ecosystems. Preliminary proposal due January 31, 2022. Med-RA deadline to receive draft documents: January 18. Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to expand our understanding of protozoan parasite persistence mechanisms and provide research tools and strategies to enable identification and credentialing of novel treatments for persistent protozoan pathogens. Due February 8, 2022. Med-RA deadline to receive draft documents: January 26. New York Stem Cell Foundation: Stem Cell and Neuroscience Investigator Awards Robertson Stem Cell Investigator Awards NYSCF is soliciting applications from early career investigators for awards to be used for exploring the basic biology and translational potential of stem cells. The aim of this initiative is to support highly innovative, emerging scientists whose pioneering approaches have the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. This career development award provides up to $1.5 million in flexible funding over 5 years. No institutional overhead is provided. To be eligible, candidates must: * Have completed one or more of the following degrees: MD, PhD, DPhil * Be within 6 years of starting a faculty (professorship) or comparable position on June 1, 2022 (Note: an additional year of eligibility was added as a result of the COVID-19 crisis) * Independently supervise a research team as head of group/laboratory * Have a publication record containing articles that are innovative and high impact Due February 16, 2022. Med-RA deadline to receive draft documents: February 3. Robertson Neuroscience Investigator Awards NYSCF is soliciting applications from early career investigators for awards in neuroscience. The goal of this initiative is to foster innovative, emerging scientists whose pioneering approaches have the potential to transform the field of neuroscience. For the 2022 application cycle, applicants are invited to apply from all fields in neuroscience. NYSCF especially encourages applications from neuroscientists whose research areas may be under-supported by traditional funding mechanisms and/or underrepresented in the field as a whole. Applicants need not be working in areas related to stem cells or related areas. This career development award provides up to $1.5 million in flexible funding over 5 years. No institutional overhead is provided. To be eligible, candidates must: * Have completed one or more of the following degrees: MD, PhD, DPhil * Be within 6 years of starting a faculty (professorship) or comparable position on June 1, 2022 (Note: an additional year of eligibility was added as a result of the COVID-19 crisis) * Independently supervise a research team as head of group/laboratory * Have a publication record containing articles that are innovative and high impact Due February 16, 2022. Med-RA deadline to receive draft documents: February 3. Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation for broad protection against GAS infections. Due February 18, 2022. Med-RA deadline to receive draft documents: February 7. Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional) The goal of this Funding Opportunity Announcement (FOA) is to support research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy aging and in Alzheimer?s disease (AD) and Alzheimer?s disease-related dementias (ADRD). This FOA aims to address the need for more prospective, hypothesis-driven research to build a theoretical framework and to clearly identify the extent to which acquiring a second language impacts human brain function. Multimodal and multidisciplinary studies are highly encouraged to improve our understanding of the complex interactions between neural, environmental, and sociocultural factors and the role of bilingualism in healthy aging and in AD/ADRD. Due March 3, 2022. Med-RA deadline to receive draft documents: February 14. Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement is to support research to identify cell-specific mechanisms in biomolecular condensate (BMC) formation and function, providing novel information for the role BMCs play in diverse cell types in the context of aging and neurobiology of Alzheimer?s disease (AD) or AD-related dementias (ADRD). This research should enhance our understanding of the cell-specific mechanistic role of BMCs in aging and AD/ADRD and serve as the foundation for more comprehensive etiological studies that might lead to the development of future BMC-based therapies for age-related neurodegenerative diseases. Due March 3, 3022. Med-RA deadline to receive draft documents: February 14. Promoting Reproductive Health for Adolescents and Adults with Disabilities (R01 Clinical Trial Optional) This Funding Opportunity Announcement invites grant applications that address gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence to adulthood for persons with disabilities. Due March 20, 2022. Med-RA deadline to receive draft documents: March 8. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: